Background: Impaired cardiac function persists in the era of effective HIV therapy, though the etiology is unclear. We used magnetic resonance imaging (MRI) to measure intramyocardial lipid and fibrosis as possible contributors to HIV-associated myocardial dysfunction.
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In the era of widespread use of antiretroviral therapy for HIV infection, reports of higher than expected rates of systolic and diastolic dysfunction persist [1] [2] [3] [4] [5] . A recent meta-analysis of studies evaluating cardiac dysfunction in HIV in the context of antiretroviral therapy identified left ventricular (LV) systolic dysfunction in 8% and diastolic dysfunction in as many as 43% of HIV-infected adults [1] . While the long-term clinical implications of subclinical cardiac abnormalities is not clear, Moyers and colleagues [6] showed that significantly diminished LV function (e.g. ejection fraction < 40%) was a strong predictor of sudden cardiac death in a large cohort of HIV-infected patients. The etiology of impaired myocardial function in HIV is not yet fully understood, but studies have implicated traditional risk factors such as age, hypertension and smoking [1, 4] as well as antiretroviral therapy [7] and direct effects of HIV [5, 8] .
Prior investigation has demonstrated significant abnormalities of lipid deposition in various tissue compartments in HIV [9] [10] [11] [12] [13] [14] , and myocardial lipid deposition may also be increased. Advances in magnetic resonance spectroscopy (MRS) now permit reliable non-invasive quantification of intramyocardial fat content [15] . Myocardial steatosis is abnormal and likely represents subclinical myocardial injury that may ultimately lead to myocardial dysfunction [16] [17] [18] [19] [20] . Magnetic resonance tagging techniques also represent a valid and sensitive method to assess myocardial contraction through myocardial strain measurements [21] . For example, tagged MRI measurements can identify subclinical regional LV dysfunction (impaired strain) that corresponds to coronary atherosclerosis in adults without known cardiovascular disease [22] .
We hypothesized that abnormal myocardial lipid accumulation and myocardial fibrosis in HIV may be related to impairment in cardiac function. Therefore, we examined intramyocardial lipid content using MRS in a cohort of HIV-infected adults compared to healthy controls and we evaluated the relationships between measures of myocardial steatosis, fibrosis, and myocardial strain, as well as biomarkers of immune activation.
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Methods

Subjects
We prospectively evaluated 95 HIV-infected adults and 30 age-, sex-, and race- A c c e p t e d M a n u s c r i p t 6
Statistical Analysis
Group comparisons were performed using Student's t-tests or chi-square statistics as appropriate. Non-normally distributed variables (CRP, D-dimer, intramyocardial lipid content, pro-BNP, LBP, MCP-1, TIMP-1 and triglyceride level) were log transformed to approximate a normal distribution, are presented as median and interquartile range (IQR), and group differences tested using a Wilcoxon test. Two-sided p-values of p<0.05 were used to determine statistical significance. Univariate linear regression analyses were calculated to identify variables associated with intramyocardial lipid content both in the entire study population and within HIV-infected subjects only. We evaluated the relationship between years of ARV exposure and years of subclasses of ARVs (NNRTI and PI). The study was not sufficiently large to evaluate individual ARV agents.
Multivariate regressions models were constructed to include all variables identified as significant in univariate regression, as well as important potential confounders (e.g.
smoking pack-years, age, use of lipid lowering therapy). Similar analyses were performed for myocardial fibrosis and cardiac strain parameters. Major findings were retested in separate sub-analyses that excluded subjects with HCV, diabetes, and those not on ARV therapy. Statistical analyses were completed using SAS JMP® version 11.0.
Results
The study groups were similar with respect to age, sex, and race ( Table 1 ). The majority of HIV-infected subjects were receiving ARV therapy, and 84.2% had HIV viral loads below the limit of detection (<50 copies/ml). One subject not an ARV therapy was a known elite controller, all others not on ARV therapy (n=6) had detectable HIV virus.
HIV-infected subjects were more likely to have ever smoked and had greater mean smoking pack-years. More HIV-infected subjects were receiving lipid lowering therapy than controls (p=0.06) and of the subjects receiving lipid lowering therapy, 84% were receiving a statin. Metabolic parameters and biomarkers of inflammation and immune activation are presented in Table 2 . The HIV-infected group had an increased fasting glucose compared to controls, but the groups were similar with respect to insulin, HOMA-IR, and free fatty acids. LDL cholesterol was lower in the HIV-infected subjects, but there were no statistical differences in total or HDL cholesterol or triglyceride levels between the groups. Median D-dimer values were higher in the control group, but in both A c c e p t e d M a n u s c r i p t 7 groups the upper quartile was within the normal range for the assay (< 0.50 ug/mL FEU).
MCP-1 and TIMP-1 were higher in the HIV group, but there was no difference in LBP between the groups.
HIV-infected individuals had normal ejection fraction. However, there was evidence of subclinical systolic dysfunction compared to control subjects. Systolic radial strain and strain rate, as well as epicardial-endocardial circumferential strain were impaired compared to controls ( Within the HIV-infected cohort, higher levels of pro-BNP and MCP-1 were correlated with decreased radial strain (pro-BNP r=-0.28, p<0.01, MCP-1 r=-0.43, p<0.0001) as was increased LBP levels (r=-0.25, p=0.02). Each correlation remained statistically significant in subsequent sensitivity analyses in which subjects with diabetes, HCV infection or those not on ARV therapy were excluded. However, the correlations between pro-BNP, MCP-1 and LBP with radial strain were not observed within the control group, but this may have been limited by the smaller sample size of this group.
Discussion
To investigate the potential relationship between subclinical cardiac dysfunction and myocardial lipid and fibrosis, this study evaluated subjects with a broad range of exposure to HIV and its therapies, but without clinical cardiovascular disease. Despite Myocardial strain was lower in HIV-infected subjects compared to control subjects. Holloway et al.
[27] proposed their observed cardiac dysfunction in HIVinfected subjects was due to cardiac steatosis and fibrosis, but did not report a correlation between myocardial strain and these parameters. We, however, observed overall correlations between cardiac steatosis and fibrosis with depressed cardiac strain in subjects with a minor degree of focal scar that did not differ from age and gender matched controls (8-9%). Our findings strongly suggest that diffuse, rather than focal A c c e p t e d M a n u s c r i p t 10 myocardial injury, may be the sequelae of HIV infection and myocardial steatosis.
The relationship between visceral abdominal fat volume and myocardial lipid content has been well-established in obese populations [16, 31] . HIV infection is associated with increased central adiposity which conveys a two-fold increased risk in 5-year mortality [9] , but the present study is among the first to characterize the relationship between visceral adipose tissue (VAT) and intramyocardial steatosis in HIV-infected individuals. VAT, in part due to side effects of ARV exposure, was the strongest independent predictor of intramyocardial lipid. This suggests that the altered metabolic activity of the visceral fat compartment may be a driving force of observed myocardial effects. Studies of non-HIV-infected obese populations have shown that increased intramyocardial triglyceride content, which correlates with VAT, is inversely associated with stroke volume [16] . Therefore, visceral adiposity in HIV-infected individuals may increase the risk for clinical cardiac dysfunction through cardiac steatosis.
Monocyte chemoattractant protein-1 (MCP-1) is a chemokine important in monocyte and macrophage migration and is a marker of chronic inflammation and immune activation. In patients with chronic heart failure, elevated MCP-1 levels are associated with decreased left ventricular ejection fraction and, in one study, higher MCP-1 levels predicted subsequent cardiac events [32] . We found that increased MCP-1 levels were strongly associated with degree of impairment in cardiac strain.
Lipopolysaccharide binding protein, a marker of chronic inflammation and an acute phase protein made in response to lipopolysaccharide (LPS), was also associated with impaired cardiac strain in the HIV-infected cohort. In a case-control study, Sandler and colleagues [33] found sCD14, a marker of LPS mediated monocyte activation, though not associated with cardiovascular events, was a predictor of mortality in HIV. Therapeutic interventions targeted at attenuating immune activation in chronic HIV infection are under active investigation. Our data support this as an approach that may modify or reduce end organ injury that accumulates through this process.
Previously uncharacterized differences related to sex in both cardiac steatosis and cardiac fibrosis indices were observed. Female sex was an independent predictor of intramyocardial lipid content in both HIV and controls. Earlier data in HIV-infected populations suggest that women may be more susceptible than their male counterparts to A c c e p t e d M a n u s c r i p t 11 the metabolic effects of ARVs [34] . In the general population, female sex independently predicts higher myocardial fatty acid esterification and lower percent fatty acid oxidation in the left ventricle of the heart [35] , suggesting cardiomyocytes may have an increased fatty acid deposition-to-utilization ratio in females. Therefore, HIV-infected women on
ARVs may be particularly susceptible to abnormal cardiac lipid deposition. As seen in large population studies [30] , female sex was independently associated with greater myocardial fibrosis indices compared to males.
The cross-sectional design of the present study limits the interpretation of observed associations and cannot establish causality. HIV-infected and control subjects were allowed to self-refer which may have introduced bias to the sample selection.
Subjects with known cardiovascular disease, though, were excluded and therefore the abnormalities identified in cardiac steatosis and function are subclinical in nature.
Prospective longitudinal studies evaluating these characteristics in patients initiating ARVs, as well as studies with clinical cardiovascular disease endpoints are needed to fully appreciate the etiology and significance of cardiac steatosis, fibrosis, and impaired cardiac strain in HIV. Females were relatively underrepresented in the study population.
Further studies focusing on cardiovascular disease in women are needed to better examine the relationship between HIV infection and cardiac steatosis.
Our study identified increased subclinical cardiac dysfunction in association with cardiac steatosis and fibrosis in HIV-infected adults. Given the known increased risk of cardiovascular disease in persons living with HIV [36] , it is important to identify risk factors and create targeted strategies to prevent progression of global cardiac dysfunction.
We demonstrate that increased visceral adipose tissue is a strong independent predictor of myocardial steatosis, and as such, reducing visceral adiposity should be a target for strategies of lifestyle modification and cardiovascular risk reduction. Further, impaired cardiac strain tracked with markers of chronic inflammation and immune activation, which may serve as targets for the development of therapeutic strategies to optimize long-term cardiovascular health in persons living with HIV.
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